Your browser doesn't support javascript.
loading
Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease.
Menet, Romain; Bourassa, Philippe; Calon, Frédéric; ElAli, Ayman.
Afiliação
  • Menet R; Neuroscience Axis, Research Center of CHU de Québec - Université Laval, Quebec City, QC, Canada; Department of Psychiatry and Neuroscience, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
  • Bourassa P; Neuroscience Axis, Research Center of CHU de Québec - Université Laval, Quebec City, QC, Canada; Faculty of Pharmacy, Université Laval, Quebec City, QC, Canada.
  • Calon F; Neuroscience Axis, Research Center of CHU de Québec - Université Laval, Quebec City, QC, Canada; Faculty of Pharmacy, Université Laval, Quebec City, QC, Canada.
  • ElAli A; Neuroscience Axis, Research Center of CHU de Québec - Université Laval, Quebec City, QC, Canada; Department of Psychiatry and Neuroscience, Faculty of Medicine, Université Laval, Quebec City, QC, Canada. Electronic address: ayman.el-ali@crchudequebec.ulaval.ca.
Neurochem Int ; 141: 104881, 2020 12.
Article em En | MEDLINE | ID: mdl-33068684
ABSTRACT
Alzheimer's disease (AD) constitutes the leading cause of dementia worldwide. It is associated to amyloid-ß (Aß) aggregation and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Evidence suggests that the canonical Wnt pathway is deregulated in AD. Pathway activity is mediated by ß-catenin stabilization in the cytosol, and subsequent translocation to the nucleus to regulate the expression of several genes implicated in brain homeostasis and functioning. It was recently proposed that Dickkopf-related protein-1 (DKK1), an endogenous antagonist of the pathway, might be implicated in AD pathogenesis. Here, we hypothesized that canonical Wnt pathway deactivation associated to DKK1 induction contributes to late-onset AD pathogenesis, and thus DKK1 neutralization could attenuate AD pathology. For this purpose, human post-mortem AD brain samples were used to assess pathway activity, and aged APPswe/PS1 mice were used to investigate DKK1 in late-onset AD-like pathology and therapy. Our findings indicate that ß-catenin levels progressively decrease in the brain of AD patients, correlating with the duration of symptoms. Next, we found that Aß pathology in APPswe/PS1 mediates DKK1 induction in the brain. Pharmacological neutralization of DKK1's biological activity in APPswe/PS1 mice restores pathway activity by stabilizing ß-catenin, attenuates Aß pathology, and ameliorates the memory of mice. Attenuation of AD-like pathology upon DKK1 inhibition is accompanied by a reduced protein expression of beta-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE1). Moreover, DKK1 inhibition enhances vascular density, promotes blood-brain barrier (BBB) integrity by increasing claudin 5, glucose transporter-1 (GLUT1), and ATP-binding cassette sub-family B member-1 (ABCB1) protein expression, as well as ameliorates synaptic plasticity by increasing brain-derived neurotrophic factor (BDNF), and postsynaptic density protein-95 (PSD-95) protein expression. DKK1 conditional induction reduces claudin 5, abcb1, and psd-95 mRNA expression, validating its inhibition effects. Our results indicate that neutralization of DKK1's biological activity attenuates AD-like pathology by restoring canonical Wnt pathway activity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Peptídeos e Proteínas de Sinalização Intercelular / Doença de Alzheimer Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Peptídeos e Proteínas de Sinalização Intercelular / Doença de Alzheimer Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article